The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Vaccine Contract Manufacturing Market (3rd Edition) by Business Operations (Cell / Virus Banking, Analytical Testing, Formulation Development, Process Development, Fill / Finish, Regulatory Filings), Type of Expression Systems (Mammalian, Microbial, Others), Company Size (Small, Mid-sized and Large / Very Large), Scale of Operation (Preclinical, Clinical, Commercial), and Geography (North America, Europe, Asia-Pacific, Rest of the World): Industry Trends and Global Forecasts, 2021-2030

  • Lowest Price Guaranteed From USD 5,499

  • Published
    May 2021

  • Pages
    503

  • View Count
    11685

Example Insights

Vaccine-Contract-Manufacturing-Market-Context Vaccine-Contract-Manufacturing-Market-Distribution-by-Services-Provided Vaccine-Contract-Manufacturing-Market-Company-Size-and-Scale-of-Operation Vaccine-Contract-Manufacturing-Market-Distribution-of-COVID-19-Vaccine-CMO
Vaccine-Contract-Manufacturing-Market-Partnerships-and-Collaborations Vaccine-Contract-Manufacturing-Market-Mergers-and-Acquisitions Vaccine-Contract-Manufacturing-Market-Competitiveness-Analysis Vaccine-Contract-Manufacturing-Market-Capacity-Analysis
Vaccine-Contract-Manufacturing-Market-Global-Demand Vaccine-Contract-Manufacturing-Market-Distribution-by-Type-of-Services Vaccine-Contract-Manufacturing-Market-Future-Forecast

 

Overview

Taking into consideration prevalent (the COVID-19 pandemic) and anticipated future trends, the global vaccines market is expected to be worth around USD 100 billion by 2025. Recent estimates (as reported in April 2021) suggest that more than 1.06 billion doses have been administered across 172 countries, which roughly translates to 19.7 million doses per day. Although the pandemic is responsible for the current surge in the demand for vaccines, according to the WHO, the current global vaccination rate is nearly 85%. As a result, as the global population grows, the demand for manufacturing vaccines is likely to increase, as well. It is worth highlighting that the vaccine development process is characterized by the need for heavy investments in specialized infrastructure and affiliated expertise, and complex R&D and production protocols. Further, vaccine manufacturing is highly regulated, and due to increasing regulatory stringency, it is gradually becoming difficult for vaccine developers to establish in-house capabilities for the large-scale manufacturing of proprietary vaccine candidates, while ensuing compliance to the evolving standards. As a result, outsourcing vaccine manufacturing operations has become a preferred practice in this segment of the biopharmaceutical industry. The outsourcing-based operating model is common among small and mid-sized innovators, which heavily rely on capable contract manufacturing organizations (CMOs) for clinical- and commercial-scale manufacturing requirements. Over time, several big pharma players, with established in-house capabilities, have also been observed to enter into long-term business relationships with CMOs, in order to optimize internal resource utilization, manage cost of operations, and leverage the niche expertise of specialty service providers.

The contemporary contract services market for vaccines is highly fragmented, featuring a mix of small and mid-sized firms, and established players. Numerous stakeholders presently claim to be actively striving to expand their respective service portfolios; in this context, there has been substantial acquisition activity in this domain, in the recent past. As a result, several of the larger CMOs have developed the required capabilities and expertise to offer end-to-end services, ranging from vaccine development (which includes preliminary R&D, preclinical studies and clinical trials) to regulatory filings, and commercial scale production. It is worth mentioning that to fulfil the growing demand for COVID-19 vaccines and ensure minimal disruption in the supply of these vaccines, several big pharmaceutical companies (such as Bayer, Merck, and Novartis) have offered their manufacturing infrastructure for production of COVID-19 vaccines. Other recent developments in this field include capability expansions, and collaborations focused on expanding geographical presence. In the foreseen future, we expect the demand for core competencies to continue to drive sponsor companies to rely on contract service providers for various aspects of vaccine development and manufacturing. Amidst the tough competition within this domain, the availability of cutting-edge tools and technologies has emerged as a differentiating factor, offering competitive advantage to CMOs that possess them. Given the increased impetus on outsourcing vaccine manufacturing, we anticipate the vaccine contract manufacturing market to grow at a steady pace over the next decade.

Scope Of the Report

The “Vaccine Contract Manufacturing Market (3rd Edition) by Outsourced Business Operations (Cell / Virus Banking, Analytical Testing, Formulation Development, Process Development, Fill / Finish, and Regulatory Filings), Type of Expression Systems (Mammalian, Microbial, and Others), Size of the Company (Small-sized, Mid-sized and Large / Very Large), Scale of Operation (Preclinical / Clinical and Commercial), and Geography (North America (the US), Europe (UK, France, Germany, Italy and Spain), Asia (China, India, Japan and South Korea) and Rest of the World (South Africa): Industry Trends and Global Forecasts” report features an extensive study on contract service providers engaged in the development and manufacturing of vaccines. The study features in-depth analyses, highlighting the capabilities of various vaccine CMOs. Amongst other elements, the report includes:
A detailed review of the overall landscape of the vaccine contract manufacturing market, featuring a list of active CMOs and an analysis based on a number of relevant parameters, such as year of establishment, size of employee base, location of headquarters, number of vaccine manufacturing facilities, type of service(s) offered (cell / virus banking, analytical development / testing, formulation, process development, fill / finish and regulatory filings), scale of operation (preclinical, clinical and commercial), type of expression system used (mammalian, microbial and others) and type of vaccine manufactured (protein vaccine, viral vaccine, DNA vaccine, cancer vaccine, and others).

  • A detailed review of the contract manufacturing landscape for COVID-19 vaccines, featuring a list of service providers and an analysis based on type of service(s) offered (cell / virus banking, analytical development / testing, formulation, process development, fill / finish and regulatory filings) and geographical location of contract manufacturers (North America, Europe, and Asia-Pacific and Rest of the World), along with competitiveness analysis of companies based in different geographies.
  • A region-wise company competitiveness analysis, highlighting the most prominent vaccine contract manufacturers, based on supplier strength (in terms of experience), and service strength (in terms of service offerings, expression systems used, and scale of operation).
  • Elaborate profiles of the key players based in North America, Europe, and Asia-Pacific having a diverse range of capabilities for development, manufacturing and packaging of vaccines. Each profile includes an overview of the company, its financial performance (if available), information on service portfolio, vaccine manufacturing facilities, recent developments and an informed future outlook. 
  • An analysis of the collaborations that have been established since 2013, based on various parameters, such as year of agreement, type of agreement, scale of operation, type of services mentioned in the deal, type of vaccines manufactured, key therapeutic areas, and location of facility where the project is to be executed. 
  • A detailed analysis of the expansions undertaken (since 2013) by various vaccine contract manufacturing service providers for enhancing their service portfolios, based on a number of parameters, including year of expansion, purpose of expansion (capacity expansion, capability expansion, facility expansion, and new facility), geographical location of facility, scale of operation, type of service(s) offered, highlighting most active players and other details (in terms of new area added to existing facilities, if available).
  • A detailed analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired during the time period between 2013-2021, along with the geographical distribution of this activity. The analysis also depicts the relationship between important deal multiples (based on revenues), number of employees, and overall experience of the acquired company.
  • A detailed capacity analysis, taking into consideration the manufacturing capacities of various stakeholders (small, mid-sized, large / very large CMOs) in the market, based on data gathered via secondary and primary research. In addition, the study provides the distribution of global vaccine manufacturing capacity by company size (small, mid-sized, large / very large), geography (North America, Europe and Asia-Pacific), and scale of operation (preclinical / clinical and commercial).
  • An informed estimate of the annual commercial and clinical demand for vaccines (in million liters), which was further segmented as across different types of vaccines, target indications, and geographies.
  • A discussion on affiliated trends, key drivers and challenges, under a comprehensive SWOT framework, which are likely to impact the industry’s evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall industry. 
  • A discussion on the potential market drivers, such as the growing vaccines pipeline, increasing outsourcing of vaccine operations and opportunities in the Asia-Pacific region, which are likely to present in the coming years.

One of the key objectives of the report was to estimate the existing market size and future growth opportunities. Based on various parameters, such as growth of the overall vaccine market, cost of goods sold, and direct manufacturing costs, we have provided informed estimates on the evolution of the market for the period 2021-2030. The report also features the likely distribution of the current and forecasted opportunity across [A] type of expression system used (mammalian, microbial, and others), [B] scale of operation (preclinical, clinical, and commercial),  [C] company size (small-, mid-sized and large / very large), and [D] key geographical regions (North America (the US), Europe (Italy, Germany, France, Spain, and the UK), and Asia-Pacific (China, India, and Japan), and Rest of the World. In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the industry’s growth. 

The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:

  • Menzo Havenga, CEO, Batavia Biosciences and Claire Otjes, Marketing Manager, Batavia Biosciences
  • David C Cunningham, Director Corporate Development, Goodwin Biotechnology
  • Ingrid Kromann, Ex-Director – Vaccine Development (currently, the Head of CMC at CEPI)
  • Kevin Daley, Director Pharmaceuticals, Novasep Synthesis
  • Sebastian Schuck, Head of Business Development, Wacker Biotech 
  • Oliver Schub, Senior Business Development Manager, ProBioGen

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Question Answered

  • Who are the key players offering vaccine manufacturing services?
  • Which manufacturing services are commonly offered by the vaccine contract manufacturers?
  • Which partnership models are most commonly adopted by stakeholders engaged in this industry?
  • What are the key value drivers of the merger and acquisition activity within this domain?
  • What is the current capacity of vaccine contract manufacturing?
  • What is the annual commercial and clinical demand for vaccines?
  • How is the current and future market opportunity likely to be distributed across key market segments?
  • What are the anticipated future trends related to vaccine contract manufacturing?

Contents

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the likely evolution of the vaccine contract manufacturing market in the mid to long term. 

Chapter 3 provides a general introduction to vaccines. The chapter also includes an overview of the various expression systems used in the development and manufacturing of vaccines. In addition, the chapter features a brief overview of contract manufacturing and a detailed discussion on the need for outsourcing within the vaccines industry. The chapter includes a list of commonly outsourced vaccine manufacturing operations and concludes with a discussion on the associated challenges.

Chapter 4 provides an overview of the global vaccine contract manufacturing landscape, including information related to over 120 companies active in this domain. In addition, it features an in-depth analysis of the market, based on a number of parameters, such as the year of establishment, size of employee base, location of headquarters, number of vaccine manufacturing facilities, type of service(s) offered (cell / virus banking, analytical development / testing, formulation, process development, fill / finish and regulatory filings), scale of operation (preclinical, clinical and commercial), type of expression system used (mammalian, microbial and others) and type of vaccine manufactured (protein vaccine, viral vaccine, DNA vaccine, cancer vaccine, and others).

Chapter 5 provides an overview of the global COVID-19 vaccine contract manufacturing landscape, including information on over 85 players that are currently active in this domain. It features an in-depth analysis of the market, based on parameters, such as type of services offered (cell / virus banking, analytical development / testing, formulation development, process development, fill / finish and regulatory filings) and geographical location of contract manufacturers (North America, Europe, and Asia-Pacific and Rest of the World). It addition, it includes an insightful competitiveness analysis of companies based in different geographies.

Chapter 6 features a detailed company competitiveness analysis of vaccine contract manufacturers based in North America, Europe, and Asia-Pacific. The analysis compares the capabilities of companies within each geography on the basis of supplier strength (in terms of experience of contract manufacturer) and service strength (in terms of service offerings, expression systems used, and scale of operation).

Chapter 7 includes detailed profiles of the key players in the vaccine contract manufacturing market, which are based in North America. Each profile features a brief overview of the company, financial information (if available), details on its contract service offerings, manufacturing facilities, recent developments and an informed future outlook. 

Chapter 8 includes detailed profiles of the key players in the vaccine contract manufacturing market, based in Europe. Each profile features a brief overview of the company, financial information (if available), details of its contract service offerings, manufacturing facilities, recent developments and an informed future outlook. 

Chapter 9 includes detailed profiles of the key players based in Asia-Pacific. Each profile features a brief overview of the company, financial information (if available), details on its contract service offerings, manufacturing facilities, recent developments and an informed future outlook. 

Chapter 10 features a detailed analysis of the partnerships and collaborations that have been established in this domain since 2013. It includes brief description of the various partnership models (acquisition, distribution agreement, licensing agreement, manufacturing agreement, product development / commercialization agreement, product development and manufacturing agreement, process development and manufacturing agreement, process development agreement, R&D agreement, service alliance, and others) that have been adopted by stakeholders in this domain. It also includes analysis based on year of agreement, type of agreement, scale of operation, type of services mentioned in the deal, type of vaccines manufactured, key therapeutic areas, and location of facility where the project is to be executed. Further, the chapter features a world map representation highlighting the number of intercontinental and intracontinental deals.

Chapter 11 presents an analysis of the expansions that have taken place in the vaccine manufacturing industry, since 2013. It includes information on expansions focused on increasing existing capabilities, as well as setting-up of new facilities. The expansion instances that we came across were analyzed based on various relevant parameters, including year of expansion, type of expansion (capacity expansion, capability expansion, facility expansion, and new facility), geographical location of the manufacturing facility, scale of operation, type of service(s), expansion details (in terms of new area added to the existing facilities, if available), and also highlights the most active players (in terms of number of instances) in the domain.

Chapter 12 presents insights from a detailed analysis of the mergers and acquisitions that have taken place in this domain, during the period 2013-2021. It is worth mentioning that the data captured during our research was analyzed based on multiple parameters, such as year of acquisition, type of acquisition, geographical location of the companies, and type of vaccine involved.

Chapter 13 features an insightful analysis of the global / regional capacity of contract manufacturers that are engaged in the manufacturing of vaccine products. The analysis takes into consideration the individual development and manufacturing capacities of various stakeholders (small, mid-sized, large / very large CMOs) in the market, using data from both secondary and primary research. The global vaccine manufacturing capacity has been analyzed by company size (small, mid-sized, and large / very large), geographical location (North America Europe Asia-Pacific and, Rest of the World) and scale of operation (preclinical / clinical, commercial).

Chapter 14 provides estimateson the demand for vaccines (both clinically and commercially available) in the market, offering an informed opinion on the required scale of supply (in terms of vaccine manufacturing services). For the purpose of estimating the current clinical demand, we considered the active clinical studies of different types of vaccines that have been registered since 2010. The data was analyzed on the basis of various parameters, such as type of vaccines manufactured, type of indication, and geography. Further, in order to estimate the commercial demand, we considered the annual volume of vaccine doses sold, based on various parameters, such as types of vaccines and geography.
 
Chapter 15 presents an insightful market forecast analysis, highlighting the likely growth of the vaccine contract manufacturing market till the year 2030. In order to provide details on the future opportunity, our projections have been segmented on the basis of  [A] type of expression systems (mammalian, microbial, and others), [B] scale of operation (preclinical, clinical, and commercial) [C] company size (small, mid-sized and large / very large), and [D] key geographical regions (North America (the US), Europe (Italy, Germany, France, Spain, and the UK), Asia-Pacific (China, India and Japan), and Rest of the World).

Chapter 16 provides a detailed discussion on affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact industry’s evolution, including a Harvey ball analysis, highlighting the relative of each parameter in the overall market.

Chapter 17 highlights the potential growth drivers of the vaccine contract manufacturing industry. It highlights the various opportunities associated with the growing vaccine pipeline, increase in outsourcing of vaccine manufacturing operations, adoption of innovative technologies and opportunities in the Asia-Pacific region, which are likely to have a notable influence on the future of the vaccine contract manufacturing market. 

Chapter 18 features the transcripts of interviews conducted with representatives from renowned organizations that are engaged in the vaccine contract manufacturing domain. In this study, we spoke to Menzo Havenga (CEO, Batavia Biosciences) and Claire Otjes (Marketing Manager, Batavia Biosciences), David C Cunningham (Director Corporate Development, Goodwin Biotechnology), Ingrid Kromann, (Ex-Director – Vaccine Development (currently, the Head of CMC at CEPI)), Kevin Daley (Director Pharmaceuticals, Novasep Synthesis), Sebastian Schuck (Head of Business Development, Wacker Biotech), and Oliver Schub (Senior Business Development Manager, ProBioGen).

Chapter 19 is an appendix that contains tabulated data and numbers for all the figures provided in the report.

Chapter 20 is an appendix that provides the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Classification of Vaccines based on Type of Active Ingredient
3.2.1. Live, Attenuated Vaccines
3.2.2. Inactivated Vaccines
3.2.3. Subunit Vaccines
3.2.4. Toxoid Vaccines
3.2.5. DNA Vaccines

3.3. Key Components of Vaccine Formulations
3.4. Vaccine Development and Manufacturing
3.4.1. Identification of Antigen and Manufacturing Process Development
3.4.2. Production of Vaccines in Different Expression Systems
3.4.2.1. Avian Expression Systems
3.4.2.2. Bacterial Expression Systems
3.4.2.3. Embryonated Chicken Eggs and Primary Chicken Embryonic Fibroblasts (CEFs)
3.4.2.4. Insect Expression System
3.4.2.5. Mammalian Expression Systems
3.4.2.6. Plant Expression Systems
3.4.2.7. Yeast Expression Systems
3.4.3. Vaccine Manufacturing Process
3.4.3.1. Upstream Process
3.4.3.2. Downstream Process
3.4.3.3. Formulation and Fill / Finish

3.4.4. Clinical Development and Approval
3.4.5. Vaccine Supply Chain and Logistics

3.5. Vaccine Contract Manufacturing
3.5.1. Need for Outsourcing Vaccine Manufacturing Operations
3.5.2. Commonly Outsourced Operations
3.5.3. Selecting a Contract Manufacturing Partner
3.5.4. Advantages of Outsourcing Manufacturing Operations
3.5.5. Risk Factors and Challenges

4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Vaccine Contract Manufacturers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Location of Manufacturing Facilities
4.2.5. Analysis by Type of Service(s) Offered
4.2.6. Analysis by Additional Services Offered and Location of Headquarters
4.2.7. Analysis by Scale of Operation
4.2.8. Analysis by Type of Vaccine Manufactured
4.2.9. Analysis by Type of Expression System Used
4.2.10. Analysis by Type of Vaccine Manufactured and Location of Headquarters

5. COVID-19 VACCINE CONTRACT MANUFACTURERS
5.1. Chapter Overview
5.2. COVID-19 Vaccine CMOs: List of Service Providers
5.2.1. Analysis by Type of Service(s) Offered
5.2.2. Analysis by Location of Headquarters

5.3. Competitiveness Analysis of COVID-19 Vaccine Contract Manufacturers
5.3.1. Methodology
5.3.2. Assumptions and Key Parameters
5.3.3. Competitiveness Analysis: COVID-19 Vaccine Contract Manufacturers based in North America
5.3.4. Competitiveness Analysis: COVID-19 Vaccine Contract Manufacturers based in Europe
5.3.5. Competitiveness Analysis: COVID-19 Vaccine Contract Manufacturers based in Asia-Pacific and Rest of the World

6. COMPANY COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Methodology
6.3. Assumptions and Key Input Parameters
6.4. Competitiveness Analysis: Vaccine Contract Manufacturers
6.4.1. Vaccine Contract Manufacturers based in North America
6.4.2. Vaccine Contract Manufacturers based in Europe
6.4.3. Vaccine Contract Manufacturers based in Asia-Pacific

7. COMPANY PROFILES: VACCINE CONTRACT MANUFACTURERS BASED IN NORTH AMERICA
7.1. Chapter Overview
7.2. Albany Molecular Research (AMRI) / OSO Biopharmaceuticals Manufacturing (OsoBio)
7.2.1. Company Overview
7.2.2. Financial Performance
7.2.3. Vaccine-related Service Portfolio
7.2.3.1. Fill / Finish Services
7.2.3.2. Regulatory Support and Quality Assurance Services

7.2.4. Vaccine Manufacturing Facility
7.2.5. Recent Developments and Future Outlook

7.3. Catalent
7.3.1. Company Overview
7.3.2. Financial Performance
7.3.3. Vaccine-related Service Portfolio
7.3.3.1. Cell Line Development Services
7.3.3.2. Clinical Manufacturing Services
7.3.3.3. Analytical Services
7.3.3.4. Clinical Supply Services
7.3.3.5. Regulatory Support Services
7.3.4. Vaccine Manufacturing Facility
7.3.5. Recent Developments and Future Outlook

7.4. Charles River Laboratories
7.4.1. Company Overview
7.4.2. Financial Performance
7.4.3. Vaccine-Related Service Portfolio
7.4.3.1. Vaccine Development Services
7.4.3.2. Vaccine Manufacturing Services
7.4.3.3. Avian Vaccine Services

7.4.4. Vaccine Manufacturing Facility
7.4.5. Recent Developments and Future Outlook

7.5. Meridian Life Science (MLS)
7.5.1. Company Overview
7.5.2. Financial Performance
7.5.3. Vaccine-Related Service Portfolio
7.5.3.1. Cell and Virus Banking Services
7.5.3.2. Process development and Scale-up Services
7.5.3.3. Formulation and Fill / finish Services
7.5.3.4. Regulatory Support Services
7.5.4. Vaccine Manufacturing Facility
7.5.5. Recent Developments and Future Outlook

7.6. BioReliance (A Unit of Merck)
7.6.1. Company Overview
7.6.2. Financial Performance
7.6.3. Vaccine Related Service Portfolio
7.6.3.1. cGMP Cell and Virus Banking Services
7.6.3.2. Process Development Services
7.6.3.3. Biorepository Services
7.6.3.4. Contract Manufacturing Support Services

7.6.4. Vaccine Manufacturing Facility
7.6.5. Recent Developments and Future Outlook

8. COMPANY PROFILES: VACCINE CONTRACT MANUFACTURERS BASED IN EUROPE
8.1. Chapter Overview
8.2. Cobra Biologics
8.2.1. Company Overview
8.2.2. Vaccine-related Service Portfolio
8.2.2.1. Viral Vaccines and Virus related Services
8.2.2.2. DNA Vaccines and DNA related Services
8.2.2.3. Other Services

8.2.3. Vaccine Manufacturing Facility
8.2.3.1. Facilities in Europe
8.2.4. Recent Developments and Future Outlook

8.3. Eurogentec
8.3.1. Company Overview
8.3.2. Vaccine-related Service Portfolio
8.3.2.1. Manufacturing Services
8.3.2.2. Analytical and Regulatory Support Services
8.3.2.3. Other Services
8.3.3. Recent Developments and Future Outlook

8.4. IDT Biologika
8.4.1. Company Overview
8.4.2. Vaccine-related Service Portfolio
8.4.2.1. Vaccine Development Services
8.4.2.2. Vaccine Manufacturing Services
8.4.2.3. Fill / Finish Services
8.4.2.4. Labeling and Packaging Services
8.4.2.5. Storage Services
8.4.2.6. Quality Control Services
8.4.3. Vaccine Manufacturing Facility
8.4.3.1. Facility in North America
8.4.3.1.1. Maryland, US
8.4.3.2. Facilities in Europe
8.4.3.2.1. Reims, Germany
8.4.3.2.2. Dessau, Germany
8.4.4. Recent Developments and Future Outlook

8.5. Lonza
8.5.1. Company Overview
8.5.2. Financial Performance
8.5.3. Vaccine-related Service Portfolio
8.5.3.1. Process Development and Optimization Services
8.5.3.2. Commercial Manufacturing Services
8.5.3.3. Fill / Finish Services
8.5.3.4. Other Services
8.5.4. Recent Developments and Future Outlook

9. COMPANY PROFILES: VACCINE CONTRACT MANUFACTURERS BASED IN EMERGING REGIONS
9.1. Chapter Overview

9.2. GreenPak Biotech
9.2.1. Company Overview
9.2.2. Vaccine-related Service Portfolio

9.3. Hong Kong Institute of Biotechnology
9.3.1. Company Overview
9.3.2. Vaccine-related Service Portfolio
9.3.2.1. Manufacturing Services
9.3.3. Vaccine Manufacturing Facility

9.4. WuXi Biologics
9.4.1. Company Overview
9.4.2. Financial Performance
9.4.3. Vaccine-related Service Portfolio
9.4.3.1. Non-Clinical Services
9.4.3.2. Discovery and Early Diagnostic Testing Services
9.4.3.3. Manufacturing Services
9.4.3.4. Support Services
9.4.3.5. Vaccine Testing Services
9.4.4. Recent Developments and Future Outlook

9.5. Bharat Biotech
9.5.1. Company Overview
9.5.2. Vaccine-related Service Portfolio
9.5.3. Vaccine Manufacturing Facility
9.5.4. Recent Developments and Future Outlook

9.6. Biological E
9.6.1. Company Overview
9.6.2. Vaccine-related Service Portfolio
9.6.3. Vaccine Manufacturing Facility
9.6.4. Recent Developments and Future Outlook

10. PARTNERSHIPS AND COLLABORATIONS
10.1. Chapter Overview
10.2. Partnership Models
10.3. Vaccine Contract Manufacturing: List of Partnerships and Collaborations
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.3. Analysis by Type of Vaccines
10.3.4. Analysis by Scale of Operation
10.3.5. Most Active Players: Analysis by Number of Partnerships
10.3.6. Regional Analysis
10.3.6.1. Intercontinental and Intracontinental Agreements

11. RECENT EXPANSIONS
11.1. Chapter Overview
11.1.1. Vaccine Contract Manufacturing Service Providers: Recent Expansions
11.1.2. Analysis by Year of Expansion
11.1.3. Analysis by Purpose of Expansion
11.1.4. Analysis by Scale of Operation and Purpose of Expansion
11.1.5. Analysis by Company Size and Location of Headquarters
11.1.6. Analysis by Purpose of Expansion and Location of Facility
11.1.7. Analysis by Type of Service(s) Offered
11.1.8. Analysis by Purpose of Expansion and Type of Service(s) Offered
11.1.9. Most Active Players: Analysis by Number of Expansions
11.1.10. Analysis by Geographical Distribution

12. MERGERS AND ACQUISITIONS
12.1. Chapter Overview
12.2. Merger and Acquisition Models
12.3. Vaccine CMOs: Mergers and Acquisitions
12.3.1. Analysis by Year of Acquisition
12.3.2. Analysis by Type of Acquisition
12.3.3. Analysis by Geography
12.3.3.1. Continent-wise Distribution
12.3.3.2. Country-wise Distribution

12.3.4. Ownership Change Matrix
12.3.5. Most Active Players: Analysis by Number of Acquisitions

12.4. Key Value Drivers
12.4.1. Analysis by Key Value Drivers
12.4.2. Analysis by Key Value Drivers and Year of Acquisition
12.5. Valuation Analysis: Acquisition Deal Multiples

13. CAPACITY ANALYSIS
13.1. Chapter Overview
13.2. Assumptions and Methodology
13.3. Vaccine Contract Manufacturing Market: Global Production Capacity (in Million Liters)
13.3.1. Analysis by Company Size
13.3.2. Analysis by Type of Expression System Used
13.3.3. Analysis by Scale of Operation
13.3.4. Analysis by Region
13.4. Conclusion

14. DEMAND ANALYSIS
14.1. Chapter Overview
14.2. Scope and Methodology

14.3. Global Clinical Demand for Vaccines
14.3.1. Analysis by Type of Vaccine
14.3.2. Analysis by Target Indication
14.3.3. Analysis by Geography

14.4. Global Commercial Demand for Vaccines
14.4.1. Analysis by Type of Vaccine
14.4.2. Analysis by Geography

14.5. Demand and Supply Analysis
14.5.1. Demand and Supply Analysis (Scenario 1)
14.5.2. Demand and Supply Analysis (Scenario 2)
14.5.3. Demand and Supply Analysis (Scenario 3)

15. MARKET FORECAST
15.1. Chapter Overview
15.2. Forecast Methodology and Key Assumptions

15.3. Overall Vaccine Contract Manufacturing Market, 2021-2030
15.4. Vaccine Contract Manufacturing Market, 2021-2030: Distribution by Type of Expression System Used
15.5. Vaccine Contract Manufacturing Market, 2021-2030: Distribution by Scale of Operation
15.6. Vaccine Contract Manufacturing Market, 2021-2030: Distribution by Company Size

15.7. Vaccine Contract Manufacturing Market, 2021-2030: Distribution by Geography
15.7.1. Vaccine Contract Manufacturing Market in North America, 2021-2030
15.7.1.1. Vaccine Contract Manufacturing in the US, 2021-2030
15.7.1.2. Vaccine Contract Manufacturing in Rest of North America, 2021-2030
15.7.1.3. Vaccine Contract Manufacturing Market in North America for Mammalian Cell-based Operations, 2021-2030
15.7.1.4. Vaccine Contract Manufacturing Market in North America for Microbial Cell-based Operations, 2021-2030
15.7.1.5. Vaccine Contract Manufacturing Market in North America for Other Expression System-based Operations, 2021-2030
15.7.1.6. Vaccine Contract Manufacturing Market in North America for Preclinical / Clinical Scale Operations, 2021-2030
15.7.1.7. Vaccine Contract Manufacturing Market in North America for Commercial Scale Operations, 2021-2030
15.7.1.8. Vaccine Contract Manufacturing Market in North America for SmallCompanies, 2021-2030
15.7.1.9. Vaccine Contract Manufacturing Market in North America for Mid-sized Companies, 2021-2030
15.7.1.10. Vaccine Contract Manufacturing Market in North America for Large / Very Large Companies, 2021-2030

15.7.2. Vaccine Contract Manufacturing in Europe, 2021-2030
15.7.2.1. Vaccine Contract Manufacturing in Italy, 2021-2030
15.7.2.2. Vaccine Contract Manufacturing in Germany, 2021-2030
15.7.2.3. Vaccine Contract Manufacturing in France, 2021-2030
15.7.2.4. Vaccine Contract Manufacturing in Spain, 2021-2030
15.7.2.5. Vaccine Contract Manufacturing in the UK, 2021-2030
15.7.2.6. Vaccine Contract Manufacturing in Rest of Europe, 2021-2030
15.7.2.7. Vaccine Contract Manufacturing Market in Europe for Mammalian Cell-based Operations, 2021-2030
15.7.2.8. Vaccine Contract Manufacturing Market in Europe for Microbial Cell-based Operations, 2021-2030
15.7.2.9. Vaccine Contract Manufacturing Market in Europe for Other Expression System-based Operations, 2021-2030
15.7.2.10. Vaccine Contract Manufacturing Market in Europe for Preclinical / Clinical Scale Operations, 2021-2030
15.7.2.11. Vaccine Contract Manufacturing Market in Europe for Commercial Scale Operations, 2021-2030
15.7.2.12. Vaccine Contract Manufacturing Market in Europe for Small Companies, 2021-2030 
15.7.2.13. Vaccine Contract Manufacturing Market in Europe for Mid-sized Companies, 2021-2030
15.7.2.14. Vaccine Contract Manufacturing Market in Europe for Large / Very Large Companies, 2021-2030

15.7.3. Vaccine Contract Manufacturing Market in Asia-Pacific and Rest of the World, 2021-2030
15.7.3.1. Vaccine Contract Manufacturing Market in China, 2021-2030
15.7.3.2. Vaccine Contract Manufacturing Market in India, 2021-2030
15.7.3.3. Vaccine Contract Manufacturing Market in Japan, 2021-2030
15.7.3.4. Vaccine Contract Manufacturing Market in Rest of Asia-Pacific and Other Regions, 2021-2030
15.7.3.5. Vaccine Contract Manufacturing Market in Asia-Pacific and Rest of the World for Mammalian Cell-based Operations, 2021-2030
15.7.3.6. Vaccine Contract Manufacturing Market in Asia-Pacific and Rest of the World for Microbial Cell-based Operations, 2021-2030
15.7.3.7. Vaccine Contract Manufacturing Market in Asia-Pacific and Rest of the World for Other Expression System-based Operations, 2021-2030
15.7.3.8. Vaccine Contract Manufacturing Market in Asia-Pacific and Rest of the World for Preclinical / Clinical Scale Operations, 2021-2030
15.7.3.9. Vaccine Contract Manufacturing Market in Asia-Pacific and Rest of the World for Commercial Scale Operations, 2021-2030
15.7.3.10. Vaccine Contract Manufacturing Market in Asia-Pacific and Rest of the World for Small Companies, 2021-2030
15.7.3.11. Vaccine Contract Manufacturing Market in Asia-Pacific and Rest of the World for Mid-sized Companies, 2021-2030
15.7.3.12. Vaccine Contract Manufacturing Market in Asia-Pacific and Rest of the World for Large / Very Large Companies, 2021-2030

16. SWOT ANALYSIS
16.1. Chapter Overview
16.2. Strengths
16.3. Weaknesses
16.4. Opportunities
16.5. Threats
16.6. Comparison of Swot Factors

17. FUTURE GROWTH OPPORTUNITIES
17.1. Chapter Overview
17.2. Technology Upgrades to Drive Future Growth
17.3. Impending and Inevitable Shift to Single-Use Systems and Components
17.4. Advent of Virus-like Particles (VLPs)
17.5. Anticipated Increase in Investments in Infrastructure Upgrades
17.6. Evolving Client / Sponsor and CMO / CDMO Relationships
17.7. Expected Rise in Business Acquisition and Consolidation Activity

18. EXECUTIVE INSIGHTS
18.1. Chapter Overview

18.2. Batavia Biosciences
18.2.1. Company Snapshot
18.2.2. Interview Transcript: Menzo Havenga, President and Chief Executive Officer

18.3. Goodwin Biotechnology
18.3.1. Company Snapshot
18.3.2. Interview Transcript: David C Cunningham, Director Corporate Development

18.4. Statens Serum Institut
18.4.1. Company Snapshot
18.4.2. Interview Transcript: Ingrid Kromann, Ex-Director – Vaccine Development (currently, the Head of CMC at CEPI)

18.5. Novasep Synthesis
18.5.1. Company Snapshot
18.5.2. Interview Transcript: Kevin Daley, Director Pharmaceuticals

18.6. ProBioGen
18.6.1. Company Snapshot
18.6.2. Interview Transcript: Oliver Schub, Senior Business Development Manager

18.7. Wacker Biotech
18.7.1. Company Snapshot
18.7.2. Interview Transcript: Sebastian Schuck, Head of Business Development

19. APPENDIX 1: TABULATED DATA

20. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Difference Between Vaccine and Small Molecule
Figure 3.2 Classification of Vaccines
Figure 3.3 Vaccine Manufacturing Processes
Figure 3.4 Key Steps in Vaccine Transportation Process
Figure 3.5 Types of Third-Party Service Providers in the Pharmaceutical Industry
Figure 3.6 Commonly Outsourced Vaccine Development Operations
Figure 3.7 Key Factors to Consider while Selecting a CMO Partner
Figure 3.8 Risks and Challenges Associated with Contract Manufacturing
Figure 4.1 Vaccine CMOs: Distribution by Year of Establishment
Figure 4.2 Vaccine CMOs: Distribution by Company Size
Figure 4.3 Vaccine CMOs: Distribution by Location of Headquarters
Figure 4.4 Vaccine CMOs: Distribution by Location of Manufacturing Facilities
Figure 4.5 Vaccine CMOs: Distribution by Type of Service(s) Offered
Figure 4.6 Vaccine CMOs: Distribution by Additional Services Offered and Location of Headquarters
Figure 4.7 Vaccine CMOs: Distribution by Scale of Operation
Figure 4.8 Vaccine CMOs: Distribution by Type of Vaccine Manufactured
Figure 4.9 Vaccine CMOs: Distribution by Type of Expression System Used
Figure 4.10 Vaccine CMOs: Distribution by Type of Vaccine Manufactured and Location of Headquarters
Figure 5.1 COVID-19 Vaccine Contract Manufacturers: Distribution by Type of Service(s) Offered
Figure 5.2 COVID-19 Vaccine Contract Manufacturers: Distribution by Location of Headquarters
Figure 5.3 Competitiveness Analysis: COVID-19 Vaccine Contract Manufacturers based in North America
Figure 5.4 Competitiveness Analysis: COVID-19 Vaccine Contract Manufacturers based in Europe
Figure 5.5 Competitiveness Analysis: COVID-19 Vaccine Contract Manufacturers based in Asia-Pacific and Rest of the World
Figure 6.1 Vaccine Contract Manufacturers based in North America
Figure 6.2 Vaccine Contract Manufacturers base in Europe
Figure 6.3 Vaccine Contract Manufacturers based in Asia- Pacific and Rest of the World
Figure 7.1 AMRI: Annual Revenues, 2013-Q1 2017 (USD Million)
Figure 7.2 AMRI: Overview of Service Portfolio
Figure 7.3 Catalent: Revenues, 2013-2020 (USD Million)
Figure 7.4 Catalent: Revenues by Business Divisions, 2020 (USD Million)
Figure 7.5 Catalent: Vaccine-related Service Portfolio
Figure 7.6 Charles River Laboratories: Annual Revenues, 2013-2020 (USD Billion)
Figure 7.7 Charles River Laboratories: Revenues by Business Segments, 2020 (USD Billion)
Figure 7.8 Charles River Laboratories: Products and Services
Figure 7.9 Meridian Life Science: Annual Revenues, 2013-2020 (USD Million)
Figure 7.10 Merck KGaA: Annual Revenues, 2013-2020 (EUR Billion)
Figure 7.11 Merck KGaA: Annual Revenues by Business Sector, 2020 (EUR Billion)
Figure 7.12 SAFC: Contract Manufacturing Support Services
Figure 7.13 SAFC Carlsbad Facility: Vaccine Manufacturing Services
Figure 8.1 Eurogentec: Manufacturing Technologies and Capabilities
Figure 8.2 IDT Biologika: Vaccine-related Service Portfolio
Figure 8.3 Lonza: Annual Revenues, 2013-2020 (CHF Million)
Figure 8.4 Lonza: Vaccine-related Service Portfolio
Figure 9.1 Hong Kong Institute of Biotechnology: Vaccine-related Service Portfolio
Figure 9.2 WuXi Biologics: Annual Revenues, 2013-2020 (RMB Million)
Figure 9.3 WuXi Biologics: Vaccine Development Services
Figure 9.4 WuXi Biologics: Vaccine Testing Services
Figure 10.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2013-2021 (Till March)
Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 10.3 Partnerships and Collaborations: Year and Type of Partnership (2013-2021)
Figure 10.4 Partnerships and Collaborations: Distribution by Type of Vaccines
Figure 10.5 Partnerships and Collaborations: Distribution by Therapeutic Area and Type of Partnership
Figure 10.6 Partnerships and Collaborations: Distribution by Scale of Operation and Type of Partnership
Figure 10.7 Partnerships and Collaborations: Most Active Players
Figure 10.8 Partnerships and Collaborations: Regional Distribution
Figure 10.9 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Figure 11.1 Recent Expansions: Cumulative Year-Wise Trend, 2013-2021
Figure 11.2 Recent Expansions: Distribution by Purpose of Expansion
Figure 11.3 Recent Expansions: Distribution by Scale of Operation and Purpose of Expansion
Figure 11.4 Recent Expansions: Distribution by Company Size and Location of Headquarters
Figure 11.5 Recent Expansions: Distribution by Purpose of Expansion and Location of Facility
Figure 11.6 Recent Expansions: Distribution by Type of Service(s) Offered
Figure 11.7 Recent Expansions: Distribution by Purpose of Expansion and Type of Service(s) Offered
Figure 11.8 Recent Expansions: Most Active Players
Figure 11.9 Recent Expansions: Geographical Distribution
Figure 12.1 Mergers and Acquisitions: Distribution by Year of Acquisition, 2013-2021
Figure 12.2 Mergers and Acquisitions: Distribution by Type of Acquisition
Figure 12.3 Mergers and Acquisitions: Regional Distribution
Figure 12.4 Mergers and Acquisitions: Intercontinental and Intracontinental Distribution
Figure 12.5 Mergers and Acquisitions: Most Active Acquirers
Figure 12.6 Mergers and Acquisitions: Key Value Drivers
Figure 12.7 Mergers and Acquisitions: Deal Multiples Based on Revenue
Figure 13.1 Capacity Analysis: Distribution by Company Size
Figure 13.2 Capacity Analysis: Global Vaccine Contract Manufacturing Capacity based on Type of Expression System Used
Figure 13.3 Capacity Analysis: Global Contract Vaccine Manufacturing Capacity based on Scale of Operation
Figure 13.4 Capacity Analysis: Regional Distribution of Vaccine CMOs
Figure 14.1 Global Clinical Demand for Vaccines, 2021-2030 (Million Liters)
Figure 14.2 Global Clinical Demand for Vaccines, 2021-2030: Distribution by Type of Vaccine (Million Liters)
Figure 14.3 Global Clinical Demand for Vaccines, 2021-2030: Distribution by Target Indications (Million Liters)
Figure 14.4 Global Clinical Demand for Vaccines, 2021-2030: Distribution by Geography (Million Liters)
Figure 14.5 Global Commercial Demand for Vaccines, 2021-2030 (Million Liters)
Figure 14.6 Global Commercial Demand for Vaccines, 2021-2030: Distribution by Type of Vaccine (Million Liters)
Figure 14.7 Global Commercial Demand for Vaccines, 2021-2030: Distribution by Geography (Million Liters)
Figure 14.8 Global Supply and Demand Analysis for Vaccine Production: Summary of Scenario 1
Figure 14.9 Global Vaccine Contract Manufacturing: Demand and Supply (Scenario 1), 2021-2030
Figure 14.10 Global Supply and Demand Analysis for Vaccine Production: Summary of Scenario 2
Figure 14.11 Global Vaccine Contract Manufacturing: Demand and Supply (Scenario 2), 2021-2030
Figure 14.12 Global Supply and Demand Analysis for Vaccine Production: Summary of Scenario 3
Figure 14.13 Global Vaccine Contract Manufacturing: Demand and Supply (Scenario 3), 2021-2030
Figure 15.1 Vaccine Contract Manufacturing: Market Forecast Framework
Figure 15.2 Overall Vaccine Contract Manufacturing Market, 2021-2030 (USD Billion)
Figure 15.3 Vaccine Contract Manufacturing Market: Distribution by Type of Expression System Used, 2021-2030 (USD Billion)
Figure 15.4 Vaccine Contract Manufacturing Market: Distribution by Scale of Operation, 2021-2030 (USD Billion)
Figure 15.5 Vaccine Contract Manufacturing Market: Distribution by Company Size, 2021-2030 (USD Billion)
Figure 15.6 Vaccine Contract Manufacturing Market: Distribution by Geography, 2021-2030 (USD Billion)
Figure 15.7 Vaccine Contract Manufacturing Market in North America, 2021-2030 (USD Billion)
Figure 15.8 Vaccine Contract Manufacturing Market in the US, 2021-2030 (USD Billion)
Figure 15.9 Vaccine Contract Manufacturing Market in Rest of North America, 2021-2030 (USD Billion)
Figure 15.10 Vaccine Contract Manufacturing Market in North America for Mammalian Cell-based Operations, 2021-2030 (USD Billion)
Figure 15.11 Vaccine Contract Manufacturing Market in North America for Microbial Cell-based Operations, 2021-2030 (USD Billion)
Figure 15.12 Vaccine Contract Manufacturing Market in North America for Other Expression System-based Operations, 2021-2030 (USD Billion)
Figure 15.13 Vaccine Contract Manufacturing Market in North America for Preclinical / Clinical Scale Operations, 2021-2030 (USD Billion)
Figure 15.14 Vaccine Contract Manufacturing Market in North America for Commercial ScaleOperations, 2021-2030 (USD Billion)
Figure 15.15 Vaccine Contract Manufacturing Market in North America for Small Companies, 2021-2030 (USD Billion)
Figure 15.16 Vaccine Contract Manufacturing Market in North America for Mid-sized Companies, 2021-2030 (USD Billion)
Figure 15.17 Vaccine Contract Manufacturing Market in North America for Large / Very Large Companies, 2021-2030 (USD Billion)
Figure 15.18 Vaccine Contract Manufacturing Market in Europe, 2021-2030 (USD Billion)
Figure 15.19 Vaccine Contract Manufacturing Market in Italy, 2021-2030 (USD Billion)
Figure 15.20 Vaccine Contract Manufacturing Market in Germany, 2021-2030 (USD Billion)
Figure 15.21 Vaccine Contract Manufacturing Market in France, 2021-2030 (USD Billion)
Figure 15.22 Vaccine Contract Manufacturing Market in Spain, 2021-2030 (USD Billion)
Figure 15.23 Vaccine Contract Manufacturing Market in the UK, 2021-2030 (USD Billion)
Figure 15.24 Vaccine Contract Manufacturing Market in Rest of Europe, 2021-2030 (USD Billion)
Figure 15.25 Vaccine Contract Manufacturing Market in Europe for Mammalian Cell-based Operations, 2021-2030 (USD Billion)
Figure 15.26 Vaccine Contract Manufacturing Market in Europe for Microbial Cell-based Operations, 2021-2030 (USD Billion)
Figure 15.27 Vaccine Contract Manufacturing Market in Europe for Other Expression System-based Operations, 2021-2030 (USD Billion)
Figure 15.28 Vaccine Contract Manufacturing Market in Europe for Preclinical / Clinical ScaleOperations, 2021-2030 (USD Billion)
Figure 15.29 Vaccine Contract Manufacturing Market in Europe for Commercial Scale Operations, 2021-2030 (USD Billion)
Figure 15.30 Vaccine Contract Manufacturing Market in Europe for Small Companies, 2021-2030 (USD Billion)
Figure 15.31 Vaccine Contract Manufacturing Market in Europe for Mid-sized Companies, 2021-2030 (USD Billion)
Figure 15.32 Vaccine Contract Manufacturing Market in Europe for Large / Very Large Companies, 2021-2030 (USD Billion)
Figure 15.33 Vaccine Contract Manufacturing Market in Asia-Pacific and Rest of the World, 2021-2030 (USD Billion)
Figure 15.34 Vaccine Contract Manufacturing Market in China, 2021-2030 (USD Billion)
Figure 15.35 Vaccine Contract Manufacturing Market in India, 2021-2030 (USD Billion)
Figure 15.36 Vaccine Contract Manufacturing Market in Japan, 2021-2030 (USD Billion)
Figure 15.37 Vaccine Contract Manufacturing Market in Rest of Asia-Pacific and Other Regions, 2021-2030 (USD Billion)
Figure 15.38 Vaccine Contract Manufacturing Market in Asia-Pacific and Rest of the World for Mammalian Cell-based Operations, 2021-2030 (USD Billion)
Figure 15.39 Vaccine Contract Manufacturing Market in Asia-Pacific and Rest of the World for Microbial Cell-based Operations, 2021-2030 (USD Billion)
Figure 15.40 Vaccine Contract Manufacturing Market in Asia-Pacific and Rest of the World for Other Expression System-based Operations, 2021-2030 (USD Billion)
Figure 15.41 Vaccine Contract Manufacturing Market in Asia-Pacific and Rest of the World for Preclinical / Clinical Scale Operations, 2021-2030 (USD Billion)
Figure 15.42 Vaccine Contract Manufacturing Market in Asia-Pacific and Rest of the World for Commercial Scale Operations, 2021-2030 (USD Billion)
Figure 15.43 Vaccine Contract Manufacturing Market in Asia-Pacific and Rest of the World for Small Companies, 2021-2030 (USD Billion)
Figure 15.44 Vaccine Contract Manufacturing Market in Asia-Pacific and Rest of the World for Mid-sized Companies, 2021-2030 (USD Billion)
Figure 15.45 Vaccine Contract Manufacturing Market in Asia-Pacific and Rest of the World for Large / Very Large Companies, 2021-2030 (USD Billion)
Figure 16.1 Vaccine Contract Manufacturing: SWOT Analysis
Figure 16.2 Comparison of SWOT Factors: Harvey Ball Analysis

List Of Tables

Table 3.1 Vaccines: Classification based on Method of Development
Table 3.2 Live Attenuated Vaccines: Commonly Reported Adverse Events
Table 3.3 Inactivated Vaccines: Commonly Reported Adverse Events
Table 3.4 Subunit Vaccines: Commonly Reported Adverse Events
Table 3.5 Toxoid Vaccines: Commonly Reported Adverse Events
Table 3.6 Vaccine Excipients and their Functions
Table 4.1 Vaccine Contract Manufacturers: List of Service Providers
Table 4.2 Vaccine CMOs: Information on Type of Service(s) Offered
Table 4.3 Vaccine CMOs: Information on Scale of Operation
Table 4.4 Vaccine CMOs: Information on Type of Expression System Used
Table 4.5 Vaccine CMOs: Information on Type of Vaccines Manufactured
Table 5.1 COVID-19 Vaccine CMOs: List of Service Providers
Table 7.1 Vaccine CMOs: List of Profiled Companies (North America)
Table 7.2 AMRI (OsoBio): Company Overview
Table 7.3 AMRI (OsoBio): Recent Developments and Future Outlook
Table 7.4 Catalent: Company Overview
Table 7.5 Catalent: Manufacturing and Laboratory Facilities
Table 7.6 Catalent: Recent Developments and Future Outlook
Table 7.7 Charles River Laboratories: Company Overview
Table 7.8 Charles River Laboratories: Recent Developments and Future Outlook
Table 7.9 Meridian Life Science: Company Overview
Table 7.10 Meridian Life Science: Recent Developments and Future Outlook
Table 7.11 BioReliance: Company Overview
Table 7.12 BioReliance: Recent Developments and Future Outlook
Table 8.1 Vaccine CMOs: List of Profiled Companies (Europe)
Table 8.2 Cobra Biologics: Company Overview
Table 8.3 Cobra Biologics: Recent Developments and Future Outlook
Table 8.4 Eugentec: Company Overview
Table 8.5 Eurogentec: Recent Developments and Future Outlook
Table 8.6 IDT Biologika: Company Overview
Table 8.7 IDT Biologika: Recent Developments and Future Outlook
Table 8.8 Lonza: Company Overview
Table 8.9 Lonza: Recent Developments and Future Outlook
Table 9.1 Vaccine CMOs: List of Profiled Companies (Emerging Region)
Table 9.2 Hong Kong Institute of Biotechnology: Company Overview
Table 9.3 Hong Kong Institute of Biotechnology: Vaccine Contract Manufacturing Services
Table 9.4 WuXi Biologics: Company Overview
Table 9.5 WuXi Biologics: Biologics Development and Manufacturing Services
Table 9.6 WuXi Biologics: Recent Developments and Future Outlook
Table 9.7 Bharat Biotech: Company Overview
Table 9.8 Bharat Biotech: Recent Developments and Future Outlook
Table 9.9 Biological E: Company Overview
Table 9.10 Biological E: Recent Developments and Future Outlook
Table 10.1 Vaccine Contract Manufacturing: Partnerships and Collaborations, 2013-2021
Table 11.1 Vaccine Contract Manufacturing: List of Recent Expansions, 2013-2021
Table 11.2 Vaccine Contract Manufacturing: Type of Service(s) Offered
Table 12.1 Vaccine Contract Manufacturing: List of Mergers and Acquisitions, 2013-2021
Table 13.1 Capacity Analysis: Global Contract Vaccine Manufacturing Capacity
Table 14.1 Global Vaccine Contract Manufacturing Annual Supply for Outsourcing (Scenario 1), 2021-2030 (Million Liters)
Table 14.2 Global Vaccine Contract Manufacturing: Annual Supply for Outsourcing (Scenario 2), 2021-2030 (Million Liters)
Table 14.3 Global Vaccine Contract Manufacturing: Annual Supply for Outsourcing (Scenario 3), 2021-2030 (Million Liters)
Table 15.1 Vaccines in the Development Pipeline
Table 18.1 Batavia Biosciences: Key Highlights
Table 18.2 Goodwin Biotechnology: Key Highlights
Table 18.3 Statens Serum Institut: Key Highlights
Table 18.4 Novasep Synthesis: Key Highlights
Table 18.5 ProBioGen: Key Highlights
Table 18.6 Wacker Biotech: Key Highlights
Table 19.1 Vaccine CMOs: Distribution by Year of Establishment
Table 19.2 Vaccine CMOs: Distribution by Company Size
Table 19.3 Vaccine CMOs: Distribution by Location of Headquarters
Table 19.4 Vaccine CMOs: Distribution by Location of Manufacturing Facilities
Table 19.5 Vaccine CMOs: Distribution by Type of Service(s) Offered
Table 19.6 Vaccine CMOs: Distribution by Scale of Operation
Table 19.7 Vaccine CMOs: Distribution by Type of Vaccine Manufactured
Table 19.8 Vaccine CMOs: Distribution by Type of Expression System Used
Table 19.9 COVID-19 Vaccine CMOs: Distribution by Type of Service(s) Offered
Table 19.10 COVID-19 Vaccine CMOs: Distribution by Location of Headquarters
Table 19.11 AMRI: Annual Revenues, 2013-Q1 2017 (USD Million)
Table 19.12 Catalent: Annual Revenues, 2013-2020 (USD Million)
Table 19.13 Catalent: Annual Revenues by Business Divisions, 2020 (USD Million)
Table 19.14 Charles River Laboratories: Annual Revenues, 2013-2020 (USD Billion)
Table 19.15 Charles River Laboratories: Distribution of Revenues by Business Segments, 2020 (USD Billion)
Table 19.16 Meridian Life Science: Annual Revenues, 2013-2020 (USD Billion)
Table 19.17 Merck KGaA: Annual Revenues, 2013-2020 (EUR Billion)
Table 19.18 Merck KGaA: Distribution of Revenues by Business Sector, 2020 (EUR Billion)
Table 19.19 Lonza: Annual Revenues, 2013-2020 (CHF Million)
Table 19.20 WuXi Biologics: Annual Revenues, 2013-2021 (RMB Million)
Table 19.21 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2013-2021 (Till March)
Table 19.22 Partnerships and Collaborations: Distribution by Type of Partnership
Table 19.23 Partnerships and Collaborations: Distribution by Year and Type of Partnership (2013-2021)
Table 19.24 Partnerships and Collaborations: Distribution by Type of Vaccines
Table 19.25 Partnerships and Collaborations: Distribution by Therapeutic Area and Type of Partnership
Table 19.26 Partnerships and Collaborations: Distribution by Scale of Operation and Type of Partnership
Table 19.27 Partnerships and Collaborations: Most Active Players
Table 19.28 Partnership and Collaborations: Regional Distribution
Table 19.29 Recent Expansions: Cumulative Year-Wise Trend, 2013-2021
Table 19.30 Recent Expansions: Distribution by Scale of Operation and Purpose of Expansion
Table 19.31 Recent Expansions: Distribution by Distribution by Company Size and Location of Headquarters
Table 19.32 Recent Expansions: Distribution by Purpose of Expansion and Location of Facility
Table 19.33 Recent Expansions: Distribution by Types of Service(s) Offered
Table 19.34 Recent Expansions: Distribution by Purpose of Expansion and Type of Service(s) Offered
Table 19.35 Recent Expansions: Most Active Players
Table 19.36 Mergers and Acquisitions: Distribution by Year of Acquisition, 2013-2021
Table 19.37 Mergers and Acquisitions: Distribution by Type of Acquisition
Table 19.38 Mergers and Acquisitions: Regional Distribution
Table 19.39 Mergers and Acquisitions: Intercontinental and Intracontinental Distribution
Table 19.40 Mergers and Acquisitions: Most Active Acquirers
Table 19.41 Mergers and Acquisitions: Key Value Drivers
Table 19.42 Mergers and Acquisitions: Deal Multiples Based on Revenue
Table 19.43 Capacity Analysis: Global Contract Vaccine Capacity by Company Size
Table 19.44 Capacity Analysis: Global Vaccine Contract Manufacturing Capacity based on Type of Expression System Used
Table 19.45 Capacity Analysis: Global Vaccine Contract Manufacturing Capacity based on Scale of Operation
Table 19.46 Capacity Analysis: Regional Distribution of Vaccine CMOs
Table 19.47 Global Clinical Demand for Vaccines, 2021-2030 (Million Liters)
Table 19.48 Global Clinical Demand for Vaccines, 2021-2030: Distribution by Type of Vaccine (Million Liters)
Table 19.49 Global Clinical Demand for Vaccines, 2021-2030: Distribution by Target Indications (Million Liters)
Table 19.50 Global Clinical Demand for Vaccines, 2021-2030: Distribution by Geography (Million Liters)
Table 19.51 Global Commercial Demand for Vaccines, 2021-2030 (Million Liters)
Table 19.52 Global Commercial Demand for Vaccines, 2021-2030: Distribution by Type of Vaccine (Million Liters)
Table 19.53 Global Commercial Demand for Vaccines, 2021-2030: Distribution by Geography (Million Liters)
Table 19.54 Overall Vaccine Contract Manufacturing Market, Conservative, Base, and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.55 Vaccine Contract Manufacturing Market, 2021-2030: Distribution by Type of Expression System Used (USD Billion)
Table 19.56 Vaccine Contract Manufacturing Market, 2021-2030: Distribution by Scale of Operation (USD Billion)
Table 19.57 Vaccine Contract Manufacturing Market, 2021-2030: Distribution by Company Size (USD Billion)
Table 19.58 Vaccine Contract Manufacturing Market, 2021-2030: Distribution by Geography (USD Billion)
Table 19.59 Vaccine Contract Manufacturing Market in North America, 2021-2030 (USD Billion)
Table 19.60 Vaccine Contract Manufacturing Market in the US, 2021-2030 (USD Billion)
Table 19.61 Vaccine Contract Manufacturing Market in Rest of North America, 2021-2030 (USD Billion)
Table 19.62 Vaccine Contract Manufacturing Market in North America for Mammalian Cell-based Operations, 2021-2030 (USD Billion)
Table 19.63 Vaccine Contract Manufacturing Market in North America for Microbial Cell-based Operations, 2021-2030 (USD Billion)
Table 19.64 Vaccine Contract Manufacturing Market in North America for Other Expression System-based Operations, 2021-2030 (USD Billion)
Table 19.65 Vaccine Contract Manufacturing Market in North America for Preclinical / Clinical Scale Operations, 2021-2030 (USD Billion)
Table 19.66 Vaccine Contract Manufacturing Market in North America for Commercial ScaleOperations, 2021-2030 (USD Billion)
Table 19.67 Vaccine Contract Manufacturing Market in North America for Small Companies, 2021-2030 (USD Billion)
Table 19.68 Vaccine Contract Manufacturing Market in North America for Mid-Sized Companies, 2021-2030 (USD Billion)
Table 19.69 Vaccine Contract Manufacturing Market in North America for Large / Very Large Companies, 2021-2030 (USD Billion)
Table 19.70 Vaccine Contract Manufacturing Market in Europe, 2021-2030 (USD Billion)
Table 19.71 Vaccine Contract Manufacturing Market in Italy, 2021-2030 (USD Billion)
Table 19.72 Vaccine Contract Manufacturing Market in Germany, 2021-2030 (USD Billion)
Table 19.73 Vaccine Contract Manufacturing Market in France, 2021-2030 (USD Billion)
Table 19.74 Vaccine Contract Manufacturing Market in Spain, 2021-2030 (USD Billion)
Table 19.75 Vaccine Contract Manufacturing Market in the UK, 2021-2030 (USD Billion)
Table 19.76 Vaccine Contract Manufacturing Market in Rest of Europe, 2021-2030 (USD Billion)
Table 19.77 Vaccine Contract Manufacturing Market in Europe for Mammalian Cell-based Operations, 2021-2030 (USD Billion)
Table 19.78 Vaccine Contract Manufacturing Market in Europe for Microbial Cell-based Operations, 2021-2030 (USD Billion)
Table 19.79 Vaccine Contract Manufacturing Market in Europe for Other Cell-based Operations, 2021-2030 (USD Billion)
Table 19.80 Vaccine Contract Manufacturing Market in Europe for Preclinical / Clinical ScaleOperations, 2021-2030 (USD Billion)
Table 19.81 Vaccine Contract Manufacturing Market in Europe for Commercial Scale Operations, 2021-2030 (USD Billion)
Table 19.82 Vaccine Contract Manufacturing Market in Europe for Small Companies, 2021-2030 (USD Billion)
Table 19.83 Vaccine Contract Manufacturing Market in Europe for Mid-sized Companies, 2021-2030 (USD Billion)
Table 19.84 Vaccine Contract Manufacturing Market in Europe for Large / Very Large Companies, 2021-2030 (USD Billion)
Table 19.85 Vaccine Contract Manufacturing Market in Asia-Pacific and Rest of the World, 2021-2030 (USD Billion)
Table 19.86 Vaccine Contract Manufacturing Market in China, 2021-2030 (USD Billion)
Table 19.87 Vaccine Contract Manufacturing Market in India, 2021-2030 (USD Billion)
Table 19.88 Vaccine Contract Manufacturing Market in Japan, 2021-2030 (USD Billion)
Table 19.89 Vaccine Contract Manufacturing Market in Rest of Asia-Pacific and Other Regions, 2021-2030 (USD Billion)
Table 19.90 Contract Manufacturing Market in Asia-Pacific and Rest of the World for Mammalian Cell-based Operations, 2021-2030 (USD Billion)
Table 19.91 Vaccine Contract Manufacturing Market in Asia-Pacific and Rest of the World for Microbial Cell-based Operations, 2021-2030 (USD Billion)
Table 19.92 Vaccine Contract Manufacturing Market in Asia-Pacific and Rest of the World for Other Expression System-based Operations, 2021-2030 (USD Billion)
Table 19.93 Vaccine Contract Manufacturing Market in Asia-Pacific and Rest of the World for Preclinical / Clinical Scale Operations, 2021-2030 (USD Billion)
Table 19.94 Vaccine Contract Manufacturing Market in Asia-Pacific and Rest of the World for Commercial Scale Operations, 2021-2030 (USD Billion)
Table 19.95 Vaccine Contract Manufacturing Market in Asia-Pacific and Rest of the World for Small Companies, 2021-2030 (USD Billion)
Table 19.96 Vaccine Contract Manufacturing Market in Asia-Pacific and Rest of the World for Mid-sized Companies, 2021-2030 (USD Billion)
Table 19.97 Vaccine Contract Manufacturing Market in Asia-Pacific and Rest of the World for Large / Very Large Companies, 2021-2030 (USD Billion)

List Of Companies

  1. 3P Biopharmaceuticals
  2. ABEC
  3. Abenza
  4. Acambis
  5. Actavis
  6. AdaptVac
  7. Adimmune
  8. Advanced BioScience Laboratories (ABL)
  9. Advaxis
  10. Advent
  11. Aeras
  12. Aeras's Biopharmaceutical Development Center (BDC)
  13. AGC Biologics
  14. AJ Biologics
  15. Ajinomoto Bio-Pharma Services
  16. Akers Biosciences
  17. Akorn India
  18. Akshaya Bio
  19. Albany Molecular Research
  20. Alexion Pharmaceuticals
  21. Algonomics
  22. Altaris Capital Partners
  23. Altimmune
  24. Amatsigroup
  25. AmbioPharm
  26. AmpTec
  27. AnaSpec
  28. Aptuit
  29. Arabio
  30. Aragen Bioscience
  31. Arcturus Therapeutics
  32. Argonaut Manufacturing Services
  33. Aspen Pharmacare
  34. Association for Assessment and Accreditation of Laboratory Animal Care
  35. AstraZeneca
  36. Aventis Pasteur
  37. Avid Bioservices
  38. Bachem
  39. Batavia Biosciences
  40. Battelle
  41. Bavarian Nordic
  42. Baxter BioPharma Solutions
  43. Bayer
  44. Baylor College of Medicine
  45. Baylor Institute for Immunology Research (BIIR)
  46. BD Biosciences
  47. Benchmark Vaccines
  48. Bharat Biotech
  49. Bharat Serums and Vaccine
  50. Bill & Melinda Gates Foundation
  51. Bilthoven Biologicals
  52. Binex
  53. BioCell
  54. Biocon
  55. BioConnections
  56. BioConvergence
  57. Biodextris
  58. Bio-Ess Laboratories
  59. Biofabri
  60. Biofarma
  61. Biogen
  62. Bioline
  63. Biological E
  64. BioMARC
  65. Biomay
  66. Biomed
  67. Biomedical Advanced Research and Development Authority (BARDA)
  68. BioMotiv
  69. BiondVax Pharmaceuticals
  70. BioNTech
  71. BioReliance
  72. BioTechLogic
  73. BioTechnique
  74. Biotechnology and Biological Sciences Research Council
  75. Biotechnology Development for Industry
  76. Biovac
  77. BioVaxys Technology
  78. Biovest International
  79. BirgiMefar
  80. Blue Water Vaccines
  81. Boehringer Ingelheim BioXcellence
  82. Boston Children’s Hospital
  83. Brammer Bio
  84. BravoVax
  85. Bristol-Myers Squibb
  86. Bryllan
  87. Burrard Pharmaceuticals
  88. Cadila
  89. CALIXAR
  90. Canadian Animal Health Institute
  91. Cangene
  92. CARBOGEN AMCIS
  93. Catalent
  94. Celsis International
  95. Centers for Disease Control and Prevention (CDC)
  96. Century Pharmaceuticals
  97. CEPiA
  98. Cetus
  99. CEVEC Pharmaceuticals
  100. Changchun BCHT Biotechnology
  101. Charles River Laboratories
  102. Chimera Biotec
  103. China Agricultural University
  104. China National Biotec Group
  105. Chinese Center for Disease Control and Prevention
  106. Chinese University of Hong Kong
  107. Chiron Behring Vaccines
  108. Coalition for Epidemic Preparedness Innovations (CEPI)
  109. Cobra Biologics
  110. Cognate BioServices
  111. Commonwealth Serum Laboratories (CSL)
  112. Cook Pharmica
  113. CordenPharma
  114. Crucell
  115. CureVac
  116. Cytovance Biologics
  117. Daiichi Sankyo
  118. Dalton Pharma Services
  119. de Duve Institute
  120. Delpharm
  121. Deltamune
  122. Department of Defense
  123. Dermapharm
  124. Disposable Lab
  125. Dr. Reddy's Laboratories
  126. Dyadic International
  127. Dynavax Technologies
  128. EGYVAC
  129. EirGenix
  130. Emergent BioSolutions
  131. Endo International
  132. Engineering and Physical Sciences Research Council
  133. Epygen Biotech
  134. ERC Belgium
  135. EuBiologics
  136. Eurogentec
  137. European Commission
  138. European Medicines Agency
  139. ExpreS2ion Biotechnologies
  140. Exxell BIO
  141. Fareva
  142. Federation of Indian Chambers of Commerce and Industry (FICCI)
  143. Florida Biologix
  144. FluGen
  145. Frederick National Laboratory
  146. French National Agency for Research on AIDS and Viral Hepatitis
  147. Friedrich-Loeffler-Institut
  148. FUJIFILM Diosynth Biotechnologies
  149. Gallant Custom Laboratories
  150. Gamma Vaccines
  151. GAVI Alliance
  152. GC Cell
  153. GC Pharma
  154. Genentech
  155. Geneos Therapeutics
  156. GENEWIZ
  157. GenIbet Biopharmaceuticals
  158. Genopis
  159. Genzyme Polyclonals
  160. GeoVax
  161. GlaxoSmithKline
  162. GNH India
  163. Goodwin Biotechnology
  164. Grand River Aseptic Manufacturing
  165. GreenPak Biotech
  166. GreenSignal Bio Pharma
  167. Griffith University
  168. Grifols
  169. GSAL
  170. GTP Technology
  171. Guangxi Veterinary Research Institute
  172. Guangzhou Air force Hospital
  173. Haffkine Institute
  174. HALIX
  175. Harbin Veterinary Research Institute (HVRI)
  176. Health Biotech
  177. Heat Biologics
  178. Hennepin Healthcare Research Institute (HHRI)
  179. Hetero Biopharma
  180. HLL Biotech
  181. Hong Kong Institute of Biotechnology
  182. IDT Biologika
  183. IMAXIO
  184. ImevaX
  185. Immune Design
  186. Immune Targeting Systems
  187. Immunex
  188. ImmunityBio
  189. Immunobiological Technology Institute (Bio-Manguinhos)
  190. ImmunoSite Technologies
  191. ImVisioN Therapeutics
  192. Index Ventures
  193. Indian Council of Medical Research
  194. Indian Immunologicals
  195. Infectious Disease Research Institute
  196. Innovate UK
  197. INOVIO
  198. INSERM-ANRS
  199. Instituto Butantan
  200. Insud Pharma
  201. Intas Biopharmaceuticals
  202. Integrity Bio
  203. International AIDS Vaccine Initiative (IAVI)
  204. International Medica Foundation
  205. International Society for Pharmaceutical Engineering
  206. International Vaccine Institute
  207. Interros
  208. Intervacc
  209. Inviragen
  210. Irvine Pharmaceutical Services
  211. Israel Institute for Biological Research (IIB)
  212. Janssen Pharmaceuticals
  213. Janssen Vaccines & Prevention
  214. Jenner Institute
  215. JHL Biotech
  216. JHP Pharmaceuticals
  217. Johnson & Johnson
  218. JSR
  219. Jubilant HollisterStier
  220. KABS Pharmaceutical Services
  221. Kalon Biotherapeutics
  222. Kaneka
  223. Karolinska Institutet
  224. KBI Biopharma
  225. Keensight Capital
  226. Kemwell Biopharma
  227. Kitasato Daiichi Sankyo Vaccine
  228. KP Pharmaceutical Technology
  229. KU Leuven
  230. Liaoning Chengda Biological
  231. LigoCyte Pharmaceuticals
  232. Lonza
  233. LuinaBio
  234. Liminal Biosciences
  235. Magellan BioScience Group
  236. Massachusetts General Hospital
  237. MassBiologics
  238. Medicago
  239. Medicines and Healthcare products Regulatory Agency
  240. Merck
  241. Meridian Life Science
  242. MilliporeSigma
  243. Minhai Biotechnology
  244. Ministry of Health & Welfare, South Korea
  245. Minneapolis Medical Research Foundation (MMRF)
  246. Mitsubishi Gas Chemical
  247. Mitsubishi Tanabe Pharma
  248. Moderna Therapeutics
  249. MSD France
  250. Mymetics
  251. Najít Technologies
  252. Nanotherapeutics
  253. National Avian Influenza Reference Laboratory
  254. National Cancer Institute
  255. National Health Research Institute
  256. National Heart, Lung, and Blood Institute
  257. National Institute of Allergy and Infectious Diseases (NIAID)
  258. National Institutes of Health (NIH)
  259. NewLink Genetics
  260. Nitto Avecia Pharma Services
  261. Norwegian Institute of Public Health
  262. Nouscom
  263. Novartis
  264. Novasep
  265. Novavax
  266. OctoPlus
  267. Ocugen
  268. Ohio State Innovation Foundation (OSIF)
  269. Okairos
  270. Ology Bioservices
  271. Oncotest
  272. Oragenics
  273. Organisation for Economic Co-operation and Development (OECD)
  274. OSO BioPharmaceuticals Manufacturing
  275. Ottawa Hospital Research Institute (OHRI)
  276. Oxford Biomedica
  277. Oxford University
  278. Pacific GMP
  279. Panacea Biotec
  280. Panacea Pharmaceuticals
  281. Paragon Bioservices
  282. PATH
  283. Patheon
  284. PaxVax
  285. Petrovax
  286. Pfenex
  287. Pfizer
  288. Pfizer CentreOne
  289. PharmaPak
  290. PharmaSynth
  291. Phlow
  292. Pierre Fabre
  293. Piramal Pharma Solutions
  294. Polymun Scientific
  295. Porton Biopharma
  296. Praha Vaccines
  297. Precisa Medicamentos
  298. Premas Biotech
  299. Prime European Therapeuticals
  300. ProBioGen
  301. Profectus BioSciences
  302. Prometic Life Sciences
  303. Protagen
  304. PX’Therapeutics
  305. QuiaPEG Pharmaceuticals
  306. RAFAGEN
  307. Recipharm
  308. Refana
  309. Reliance Life Sciences
  310. Rentschler Biopharma
  311. Richter-Helm BioLogics
  312. RIEMSER Pharma
  313. Rommelag CMO
  314. ROVI Pharma Industrial Services
  315. Russian Direct Investment Fund (RDIF)
  316. SAFC
  317. Saiba
  318. Sanofi
  319. Sanofi Active Ingredient Solutions
  320. Sanofi Pasteur
  321. Sanofi-Aventis
  322. Sartorius Stedim Biotech
  323. Scancell
  324. Seikagaku
  325. Seoul National University Hospital
  326. Seqirus
  327. Serum Institute of India
  328. Shandong Zhaoxin Bio-tech
  329. Shanghai Laboratory Animal Center
  330. ShangPharma Innovation
  331. Shasun Pharmaceuticals
  332. Shenzhen Kangtai Biological Products
  333. SialoCarb
  334. Sichuan Agricultural University
  335. Siegfried
  336. Sigma-Aldrich
  337. SK Bioscience
  338. SK Chemicals
  339. Soligenix
  340. South African Tuberculosis Vaccine Initiative (SATVI)
  341. South China Agricultural University
  342. Spicona
  343. SpyBiotech
  344. Stabilitech Biopharma
  345. State Secretariat for Education, Research and Innovation
  346. Statens Serum Institut
  347. Stellar Biotechnologies
  348. Sumagen
  349. Swissfillon
  350. Symbiosis Pharmaceutical Services
  351. SynCo Bio Partners
  352. Syngene
  353. Synthelis
  354. Takara Bio
  355. Takeda Pharmaceuticals
  356. Temasek Life Sciences Ventures
  357. The Coalition for Epidemic Preparedness Innovations (CEPI)
  358. The Friedrich-Loeffler-Institut
  359. The Hong Kong Jockey Club Charities Trust
  360. The Wistar Institute
  361. Themis Medicare
  362. TheraVectys
  363. Thermo Fisher Scientific
  364. Thomas Jefferson University
  365. Tianjin CanSino Biotechnology
  366. Tonix Pharmaceuticals
  367. Transgene
  368. Translate Bio
  369. Unitech Pharmaceuticals
  370. United Nations International Children's Emergency Fund (UNICEF)
  371. United States Army Medical Research Institute of Infectious Diseases
  372. Univercells
  373. Universitätsklinikum Tübingen
  374. University of Copenhagen
  375. University of Iowa Pharmaceuticals
  376. University of Maryland
  377. University of Oxford
  378. University of Pennsylvania
  379. University of Tokyo
  380. University of Wisconsin - Madison
  381. Upperton Pharma Solutions
  382. Vaccibody
  383. Vaccine and Infectious Disease Organization–International Vaccine Centre (VIDO- InterVac)
  384. Vaccines Manufacturing and Innovation Centre (VMIC)
  385. Vaccitech
  386. VACSERA
  387. Valerius Biopharma
  388. Valneva
  389. Vaxart
  390. Vaxess Technologies
  391. Vaxin
  392. Vetter Pharma
  393. VGXI
  394. Vibalogics
  395. VIRCHOW BIOTECH
  396. Vivalis
  397. Vipassana Research Institute (VRI)
  398. Vybion

PRICING DETAILS

USD 5,499

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com